Justen Rudolph, MD
Internal Medicine · Billings, MTNPI 1780609610
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Abbott at 29.0% of the total. Reporting peaked in 2022 at $560 and has fallen 57.3% since, to $239 in 2025. Among internal medicine clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 36 payments — averaging $41.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$435
- Medtronic$320
- Dexcom, Inc.$153
- Tandem Diabetes Care, Inc.$132
- Insulet Corporation$109
- BETA Bionics, Inc.$96
- plus $256 from 8 others
Across 8 payments — averaging $12,727 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$102K
What the payments were for
- Food & beverage$1,47598%
- Education$262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 10 | $435 |
| Medtronic | 3 | $320 |
| Dexcom, Inc. | 3 | $153 |
| Tandem Diabetes Care, Inc. | 1 | $132 |
| Insulet Corporation | 1 | $109 |
| BETA Bionics, Inc. | 1 | $96 |
| AstraZeneca | 5 | $74 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| E.r. Squibb & Sons, L.L.C. | 3 | $38 |
| Boehringer Ingelheim | 2 | $28 |
| Novo Nordisk | 1 | $26 |
| Lilly USA, LLC | 1 | $16 |
| Bayer | 1 | $13 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,501 in reported general payments places this provider in the 90th percentile of 244 internal medicine providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 176 | $207,493 |
| OzempicSemaglutide | 134 | $173,600 |
| JardianceEmpagliflozin | 99 | $116,767 |
| JanuviaSitagliptin Phosphate | 66 | $61,815 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 47 | $56,784 |
| Tresiba Flextouch U-100Insulin Degludec | 73 | $54,482 |
| TrulicityDulaglutide | 39 | $50,098 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $45,896 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 30 | $42,985 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 18 | $35,151 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $29,671 |
| RybelsusSemaglutide | 17 | $24,133 |
| Novolog FlexpenInsulin Aspart | 96 | $21,712 |
| HumalogInsulin Lispro | 56 | $20,412 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $20,389 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humulin 70-30, Insulin Lispro | $16 | $283,828303 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog | $26 | $253,097247 claims |
| Boehringer IngelheimJardiance | $28 | $116,76799 claims |
| Sanofi-aventis U.S. LLCLantus | $50 | $9,22857 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 244 internal medicine providers in Montana.
Other internal medicine in Billings
- Joseph PeilaBillings$148K
- Kari KaleBillings$83K
- Tracy RauschBillings$11K
- Brian HessBillings$8K
- Jessica HogeBillings$4K
- Michael MetzgerBillings$1K
- Lucinda HusbyBillings$659
- Michael HaganBillings$261
- Faranak ArganiBillings$220
- Hayley MillerMissoula$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.